ESC 2020 — HFrEF: empagliflozin cuts hospitalization, cardiovascular death risks


  • Pavankumar Kamat
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Empagliflozin significantly reduced the risk for cardiovascular death or heart failure hospitalization in patients with chronic heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.
  • Empagliflozin was also associated with a slower rate of decline in renal function.

Why this matters

  • The 25% reduction in the risk for cardiovascular death or heart failure hospitalization with empagliflozin is comparable with that reported for dapagliflozin in the DAPA-HF trial.

Study design

  • EMPEROR-Reduced trial: patients with class II, III, or IV heart failure and ejection fraction 40%, with or without diabetes, were randomly assigned to empagliflozin 10 mg once daily (n=1863) or placebo (n=1867).
  • Primary endpoint was a composite of cardiovascular death or hospitalization for heart failure.
  • Funding: Boehringer Ingelheim; Eli Lilly.

Key results

  • During a median follow-up of 16 months, the primary endpoint was met in 19.4% of patients in the empagliflozin group vs 24.7% of patients in the placebo group (HR, 0.75; 95% CI, 0.65-0.86).
  • The effect of empagliflozin on the primary outcome was consistent across patients:
    • With diabetes: HR, 0.72 (95% CI, 0.60-0.87); and 
    • Without diabetes: HR, 0.78 (95% CI, 0.64-0.97).
  • Total hospitalizations for heart failure were lower in the empagliflozin group than the placebo group (HR, 0.70; 95% CI, 0.58-0.85).
  • The empagliflozin group had a slower annual rate of decline in the estimated glomerular filtration rate than the placebo group (–0.55 vs –2.28 mL/minute/1.73 m2 of body surface area/year; P<.001>
  • Adverse renal outcomes occurred in 30 patients in the empagliflozin group and 58 patients in the placebo group (HR, 0.50; 95% CI, 0.32-0.77).
  • Uncomplicated genitourinary tract infections were more frequent in the empagliflozin group than the placebo group.

Expert commentary
Principal investigator, Milton Packer, MD: "The combined results of EMPEROR-Reduced together with DAPA-HF now establish SGLT2 inhibition with empagliflozin and dapagliflozin as a new cornerstone of the treatment of heart failure. The other three cornerstones are angiotensin receptor–neprilysin inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. Patients with HFrEF should be receiving all four drugs."